Merck KGaA launches donation program for praziquantel in Sudan

27 August 2013

German health care and chemicals firm Merck KGaA (MRK: DE) has donated six million praziquantel tablets as part of a World Health Organization program to treat Schistosomiasis.

The campaign has started in Sudan where an estimated 5.8 million people – around 15% of the total population – require treatment for schistosomiasis, the second most prevalent tropical disease in Africa after malaria.

This is the first time that Sudan is benefiting from Merck’s praziquantel donation to the WHO. The total value of the medicines is around 2.4 million Sudanese pounds (nearly $533,800).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK